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Introduction: We describe a simplified distributional cost effectiveness analysis based on aggregate 
data to estimate the health inequality impact of public health interventions.  
Methods: We extracted data on costs, health outcomes expressed as quality adjusted life years 
(QALYs), and target populations, for interventions within NICE public health guidance published up 
to October 2016.  Evidence on variation by age, sex and index of multiple deprivation informed 
socioeconomic distributions of incremental QALYs, health opportunity costs, and the baseline 
distribution of health.  Total population QALYs, summary measures of inequality and a health equity 
impact plane show results by intervention, and by guideline.  A value for inequality aversion from a 
general population survey in England let us combine impacts on health inequality and total health into 
a single measure of intervention value.  
Results: Our estimates suggest that of 134 interventions considered by NICE: 70 (52%) reduce 
inequality and increase health; 21 (16%) involve a trade-off between improving health and improving 
health inequality; and 43 (32%) reduce health and increase health inequality.  Fully implemented, the 
potential impact of all recommendations was 23,336,181 additional QALYs for the population of 
England and Wales, and a reduction of the gap in quality adjusted life expectancy between the 
healthiest and least healthy from 13.78 to 13.34 QALYs.  The combined value of the additional health 
and reduction in inequality was 28,723,776 QALYs.
Discussion: Our analysis takes account of the fact that existing public health spending likely benefit 
the most disadvantaged.  This simple method applied separately to economic evaluation produces 
evidence of intervention impacts on the distribution of health that is vital in determining value for 
money when health inequality reduction is a policy goal.


































































In the UK, no formal approach prescribes how health inequality impacts should inform public health 
investment decisions.  In England women and men in the most deprived areas live up to 9 years 
fewer, and have up to 20 fewer years in good health, compared to those in the least deprived areas.(1)  
The reduction of health inequalities associated with socioeconomic factors is a prominent social goal, 
demonstrating that societies regard these inequalities as unfair and value lessening of inequalities 
alongside improving health.(2, 3)  It has been argued that public health interventions can tackle this 
objective through their focus on lifestyle changes and other social determinants of health.(4, 5)   
The National Institute for Health and Care Excellence (NICE) produces public health guidelines that 
recommend interventions for provision by national and local healthcare commissioners, or within the 
wider public and private sectors.  NICE’s equality objectives note that public health guidance in 
particular is concerned with tackling health inequalities associated with underlying socioeconomic 
factors and with inequities in access for certain disadvantaged groups.(6)  The current guidance does 
not describe a process by which Public Health Advisory Committees (PHACs) should take account  of 
impact on health inequalities in their recommendations.  A formal review of the available evidence 
supported with expert testimony and economic evaluation informs their recommendations.  The 
economic evaluations estimate the scale of the health benefits produced for a given investment in an 
intervention.  The PHAC make a judgement about whether the health benefits are valuable compared 
to alternative uses of the same resources.  However, the economic evaluations do not currently 
evaluate the distribution of outcomes within the population.  
Evidence on the health inequality impact of interventions presented to PHACs is typically qualitative 
and pertains to the characteristics of the target population. This informs the likely socioeconomic 
distribution of the benefits of the intervention, but fails to account for the distribution of the benefits 
produced by investing the intervention costs in other public health activities. This omission of 
opportunity cost prevents estimation of the magnitude of the inequality impact.  The socioeconomic 
distribution of health opportunity costs depends on the characteristics of individuals that benefit from 
existing services.  Where health inequalities are a policy concern, the magnitude of the net health 
inequality impact is relevant to determining value for money.  Producing recommendations without 
information on health inequality impacts risks failing to promote the most valuable interventions.  
In principle a formal distributional cost-effectiveness analysis could evaluate health inequality 
impacts to support each public health guideline.(7, 8)  In the absence of bespoke distributional 
analysis we demonstrate a method for conducting quantitative inequality impact assessment using 
available aggregate data.   We apply this to NICE guidelines conducted between 2006 and 2016 to 

































































estimate how the public health interventions considered affect the distribution of health, taking into 
account variation in health outcomes by age, gender and socioeconomic groups.  
Methods
The methods are based on distributional cost-effectiveness analysis, and we focus on change in 
lifetime health inequality across the whole population.(7)  Figure 1 shows the steps in combining 
information on additional costs and health outcomes produced by standard economic evaluation with 
routine data about the distribution of targeted health problems, and prior knowledge of health 
opportunity costs, according to age, gender, socioeconomic status.  In essence, this scales up average 
costs and health outcomes using patient population numbers, and disaggregates them to describe the 
distribution of health benefits by age, gender and socioeconomic status.  We show the calculations for 
public health guideline 43 (Hepatitis B and C testing) in Box 1.  Combining the distributions of 
intervention impacts with a baseline distribution of health shows how interventions and public health 
recommendations might affect lifetime health inequality in the English population.  We used quality 
adjusted life years (QALYs) and quality adjusted life expectancy (QALE) as our measure of health, 
and the Index of Multiple Deprivation (IMD) as our measure of socioeconomic status.(9)  
We describe seven stages of analysis: 
(i) Extract incremental costs and health benefits and size of the target population;
(ii) Estimate the distribution of population health benefits by gender and socioeconomic status;
(iii) Convert population costs into health opportunity costs;
(iv)  Estimate the distribution of population health opportunity cost by gender and socioeconomic 
status;
(v) Calculate the net health impact (health benefit minus health opportunity cost) for gender and 
socioeconomic subgroups;
(vi)  Combine net health impacts with a baseline distribution of lifetime health;
(vii) Calculate inequality measures on the pre- and post-intervention health distributions to 
summarise health inequality impact.
 
(i) Extract incremental costs and health benefits and size of the target population

































































We reviewed cost-effectiveness evidence and the associated PHAC recommendations for NICE 
public health guidance issued between March 2006 and October 2016. We extracted information from 
guidance documents, economic modelling reports and costing templates.  We excluded guidelines if: 
(i) no economic modelling was conducted; (ii) the economic modelling did not use QALYs as a health 
outcome measure; (iii) incremental costs and QALYs were not reported separately; (iv) hypothetical 
analyses were conducted rather than modelling specific interventions; (v) the guideline was obsolete. 
For each intervention we extracted the PHAC recommendation and the per recipient incremental costs 
and QALYs that formulated the base-case incremental cost-effectiveness ratios.  These represent the 
present value of the costs and QALYs accruing over the time horizon of the underlying cost-
effectiveness analysis, for which the NICE reference case indicates the use of an annual discount rate 
of 3.5%.  To estimate the number of recipients we extracted population size estimates from NICE 
documentation, and if unavailable, from alternative sources including previously published studies 
and national population statistics.  Where no specific intervention was explicit in PHAC 
recommendations, we used the Committee's consideration of the cost effectiveness evidence to inform 
assumptions about whether the intervention would fall under the general recommendation.  Where the 
economic evidence included a range rath r than a single estimate of cost-effectiveness for an 
intervention, we extracted the best and worst case, with the best case used for our primary analysis.
(ii) Estimate the distribution of population health benefits by gender and socioeconomic status 
We multiplied the target population size by the per person QALY gain to calculate the incremental 
population health benefit for each intervention.  This value represents the upper limit of health gains 
as it entails every person in the eligible population receiving the intervention (i.e. 100% reach and 
100% implementation) and does not account for any proportion of the population that may already be 
in receipt of the intervention.
To estimate the size of each gender and socioeconomic subgroup within a target population we first 
categorised interventions as: (i) targeting specific diseases, such as Type 2 diabetes; (ii) targeting 
health behaviours, such as smokers; or (iii) targeting disadvantaged groups such as low income or 
high deprivation populations.
For interventions targeting diseases, we mapped those diseases to three-digit International 
Classification of Disease (ICD) codes.  We then calculated subgroup sizes based on the corresponding 
proportion of NHS hospital activity by gender, IMD and ICD code for that group using Hospital 
Episode Statistics (HES) (2011-12 and 2012-13).  For interventions targeted by age, we used data 
from the relevant age band.  Where interventions targeted behaviours, we searched for data sources 
that reported behaviour distribution by gender and IMD.  For interventions specifically targeting low 

































































income, disadvantaged or deprived groups we made a simplifying assumption that the health benefits 
would accrue to the most deprived fifth of the population in terms of IMD.  
(iii) Convert population costs into health opportunity costs
We calculated incremental population costs by multiplying the target population size by the per 
person incremental cost. As costs represent investments that could be spent elsewhere, namely other 
public health interventions, we converted them into health losses using an estimate of the health 
opportunity cost per pound of public sector expenditure. This value signifies the cost per QALY of 
services that could otherwise have been funded (or can be introduced if a public health intervention is 
cost saving).  We use a value of £20,000 per QALY for the base case analysis, which corresponds to 
the lower bound of the health sector cost-effectiveness threshold used within NICE.(10) If this figure 
is overestimated or if public health activities are more efficient than medical care activities this value 
underestimates health opportunity costs.(11-13)
(iv) Estimate the distribution of population health opportunity cost by gender and 
socioeconomic status
We found no published estimate of the socioeconomic gradient for marginal changes in public health 
expenditure, and so we assumed the same gradient as observed in NHS funded interventions.  The 
gender and socioeconomic distribution of population health gains from marginal changes in NHS 
expenditure has recently been estimated.(14)  We use this to represent the distribution of the health 
benefits that would have been produced by alternative public health interventions.  The distribution 
provides the proportion of the marginal QALY gain that would accrue to each gender and IMD 
subgroup, and when multiplied by the population health opportunity costs for each intervention this 
provides the subgroup health opportunity costs.
(v) Calculate the net health impact for gender and socioeconomic subgroups
The population net health impact by intervention and subgroup is the difference between the 
incremental population health benefits and incremental population health opportunity costs.  The 
impact by guideline is the sum of the costs and benefits of all interventions recommended within a 
guideline.  Where a guideline included recommendations for multiple interventions that would be 
mutually exclusive from an individual perspective we assumed an even split in utilisation across each 
intervention in the target population.

































































(vi) Combine net health impacts with a baseline distribution of lifetime health
The baseline distribution of health represents existing health inequality by gender and socioeconomic 
status across the population in England and Wales.(15)  The incremental net health effects of each 
intervention or guideline added to this baseline provide a picture of health inequality following the 
implementation of the intervention or guideline.  This describes the impact of interventions at the 
level of the population of England and Wales.  
(vii) Calculate inequality impact measures
We chose the slope index of inequality (SII) and the relative index of inequality (RII) to summarise 
inequality in the distribution of health.(16)  The SII is commonly used in public health research when 
examining absolute inequality in life expectancy by IMD.  It is obtained by fitting an ordinary least 
squares model to estimate the slope or health gradient, and interpreted as the absolute difference in 
QALE when moving from the least to most healthy in the population. The RII is the SII divided by 
the mean QALE, and represents the relative change in QALE when moving from the least to most 
healthy. The net inequality impact is the difference between SII or RII value pre- and post-
intervention.  We report the reduction such that positive values indicate interventions estimated to 
reduce health inequality.
We combined the impacts on total population health and health inequality into a single indicator of 
value by first summarising inequality in the distribution using the Atkinson and Kolm indices.(17-19)  
These indices on their own summarise the magnitude of relative and absolute inequality respectively, 
and in essence assign a weight to each individual's QALE that decreases as the individual’s rank in 
the distribution of lifetime health increases.  A perfectly equal distribution of health results in an 
inequality index of 0, and a perfectly unequal distribution results in an index equal of 1.  The weights 
and the value of improvements in total population health relative to the value of reduction in 
inequality are determined by an inequality aversion parameter, which signifies the level of concern for 
health inequality.  The higher the inequality aversion parameter, the greater the priority to reducing 
health inequality compared to increasing overall health.  We used inequality aversion parameters 
estimated in a survey of the general public in England that asked respondents to choose between an 
intervention that provided more health overall and one that provided less health overall but reduced 
the gap in health achievement between the richest and poorest.(20)  The estimated inequality aversion 
parameters are 10.95 for the Atkinson  and 0.15 for the Kolm . Given the initial levels of quality-
adjusted life expectancy presented to study participants, these figures suggest a weight for health 
gains to the poorest fifth of people between 6 and 7 times as high as incremental gains to the richest 
fifth.

































































When subtracted from one and multiplied by the mean level of health, the Atkinson and Kolm indices 
can be used to summarise the value of a distribution of health in terms of the ‘equally distributed 
equivalent’ (EDE) level of health.  The equally distributed equivalent is the level of population health 
(expressed in QALYs), that if provided uniformly to everyone in a population, would yield the same 
amount of social welfare to the distribution of health being evaluated. An intervention estimated to 
reduce health inequality will have an equally distributed equivalent health impact more positive than 
its net population health impact.  Conversely, interventions that increase health inequality would have 
an equally distributed equivalent more negative than their net population health impact, with the 
difference showing the loss of social welfare in terms of QALYs.  
Sensitivity analyses
To assess the sensitivity of the results to the estimated cost per QALY of services that could otherwise 
have been funded (or introduced using resources freed up by cost saving public health interventions) 
we varied the value from its base case of £20,000 between £2,000 to £50,000. We explore sensitivity 
to the level of relative inequality aversion by varying the inequality aversion parameter used to 
calculate the Atkinson index from its base case of 10.95 between 0 and 20.  We also investigated the 
differences in our results when using the costs and health estimates associated with the worst case 
scenario for those interventions where multiple cost-effectiveness results were reported.
Results
The final dataset consisted of 33 guidelines covering 134 discrete interventions. Detail of the included 
guidelines (Table A1), flow diagram (Figure A1) and exclusions for data extraction (Table A2), full 
results by intervention (Table A4) and full results of sensitivity analyses are provided in an online 
supplement.  
Table 1 summarises the net population health and inequality impacts of interventions, and Figure 2 
and Figure 3 show the interventions’ locations on the health equity impact plane, separated according 
to whether they were recommended by the PHAC.  Estimated SII reductions varied between -0.02 to 
0.36, suggesting that the maximum a single intervention could reduce the gap in QALE between the 
least and most healthy from its baseline value of 13.78 was by 0.36 QALYs, and at most a single 
intervention could increase the gap by 0.02 QALYs.  At the population level of England and Wales, 
the majority of interventions had small impacts on health inequality (interquartile range for change in 
SII -0.0002 to 0.001).  Ten percent of interventions were associated with reductions in SII of 0.06 or 
greater.  Positive correlation was observed between net population health impact and SII reduction 
(Pearson correlation coefficient = 0.94).  The change in Atkinson index indicated improvement in 

































































social welfare for 73 (86%) of interventions recommended by the PHAC and 15 (31%) of 
interventions that were not recommended by the PHAC.
Table 2 and Figure 4 show the results of full implementation of all recommendations by guideline. 
Eighteen (60%) were estimated to increase total population health and reduce health inequality; four 
(13%) were estimated to reduce total population health and increase health inequality; and eight 
(27%) involved a trade-off.  Estimated net population health benefits range from -1.1 million QALYs 
(NG6) to 10.9 million QALYs (PH50). Health inequality impacts range from an increase in SII of 
0.02 (NG6) to a reduction by 0.23 (PH50).  The guidelines where the value of health gains are 
reduced by the fact that they increase inequality in the distribution of health are PH41 and NG34 
(increase in absolute inequality only), and PH17, PH20 and NG21 (increase in relative and absolute 
inequality).  The equally distributed equivalent indicated that social welfare would increase from 
recommendations in all but four guidelines (PH29, PH31, PH54, NG6), all of which were associated 
with negative changes in population health.  The potential cumulative impact across all guidelines was 
an additional 23,336,181 QALYs in the population of England and Wales and a reduction in SII of 
0.44.  The equally distributed equivalent health from full implementation of recommendations across 
all guidelines was 28,723,776 QALYs, implying that the inequality reduction is equivalent in worth to 
an additional 5.4 million QALYs.
We estimated different measures of relative inequality and absolute inequality, and found little 
disagreement between them.  For two guidelines (PH41 and NG34) relative inequality measured by 
Atkinson index reduced while absolute inequality measured by Kolm index and SII increased, and for 
two more (PH3 and PH24) the SII increased but Atkinson and Kolm indexes indicated a reduction in 
inequality.  The sensitivity analyses indicated that increasing the value of the health opportunity cost 
above £20,000 per QALY had little impact (Figure A2 in online supplement).  However, the 
estimated cumulative reduction in SII fell as the cost per QALY of alternative investments reduced, to 
0.42 using £10,000 per QALY and to 0.27 using £2,000 per QALY.  The ranking of guidelines in 
terms of equally distributed equivalent health impact was sensitive to changes in the inequality 
aversion parameter, with a change of rank observed for 12 out of 30 guidelines when the inequality 
aversion was increased from 0 to a value of 20 (Figure A3 in online supplement).  However, overall 
conclusions about the direction of change in social welfare were less sensitive and changed for only 1 
out of 30 guidelines.  Using worst case estimates for incremental costs and QALYs in general reduced 
estimated reductions in health inequality (Table A3 in online supplement).
Discussion

































































The method we propose produces quantitative information on health inequality impacts from the 
evidence routinely provided for the formation of public health recommendations.  Equally distributed 
equivalent health calculations place a greater value on health gains if they reduce inequality in 
lifetime health.  This prioritises an additional QALY to someone with low quality adjusted life 
expectancy over an additional QALY to someone with high quality adjusted life expectancy.  New 
public health interventions are often funded with resource that would have been used for alternative 
public health activities, and this method ensures that health opportunity costs contribute to the 
estimates of net health inequality impact.  
The moderate positive correlation between cost effectiveness and health inequality reduction in this 
sample suggests that recommendations based on cost effectiveness alone might coincide with 
decisions that incorporate concern for health inequality, but not always.  The majority of PHAC 
recommendations were for interventions that reduce health inequality; where this is the case focussing 
on population health gains alone routinely undervalues investment in public health interventions.  
This is important where public health interventions compete for funds with downstream healthcare 
interventions, which may have less scope to reduce inequality.    
If health inequalities influence PHAC recommendations, a lower probability of recommendation 
would be expected for interventions that increase population health and increase health inequality 
compared to those that increase population health and reduce health inequality.  Similarly, we would 
expect a higher probability of recommendation for interventions that reduce population health but 
reduce health inequality compared to interventions that reduce population health and increase health 
inequality.  The small sample of trade-offs we found does little to inform this, and we did not search 
for qualitative discussion of inequality in the considerations section of the guidelines.  Overall, we 
found that PHAC recommendations were highly concordant with social welfare.  Some PHAC 
recommendations improved health but increased absolute inequality in health.  Our analysis indicates 
that society values the associated increase in population health associated with these 
recommendations (5.6 million QALYs) sufficiently to accept the increased health inequality (increase 
in SII of 0.005).
We systematically extracted data from published NICE guidelines and used an empirical estimate of 
the socioeconomic distribution of the health opportunity cost to represent the potential harms from 
diverting resources from alternative activities.  However, we made a number of simplifications that 
are worth consideration in future applications of this method.  We did not attempt to characterise 
PHAC considerations regarding the quality of evidence nor the impact of uncertainty.  Our estimates 
represent the maximum possible impact as we did not search for evidence on differential uptake 
between population groups and present our results in terms of full implementation of the 
interventions.  Where interventions are more likely to be utilised in least deprived groups, as can be 

































































the case where uptake relies on individual agency, we will have overestimated reductions in health 
inequality.(21, 22)  The method we propose can easily incorporate differential uptake by distributing 
the population health benefits only to the proportion of each group assumed to utilise the intervention.    
We also did not search for evidence of differential efficacy.  Determining the impact of this on health 
inequality impacts is not straightforward as the relationship to average QALY gains may be non-
linear and counterbalanced by interaction with differential baseline risks.  Evidence for differential 
efficacy between population groups can guide the use of full distributional cost effectiveness analysis 
in place of this simplified approach.
The value used to convert costs into health opportunity costs is a significant driver of the results, 
which demonstrates the importance of getting this value right for any formal appraisal process. Since 
opportunity costs fall heaviest on the poorest and least healthy, inequality increases with the health 
opportunity cost for cost increasing interventions. If the value we use is too high, we will have 
overestimated improvements in total population health, reduction in health inequality and 
improvement in social welfare.  The £20,000 per QALY used by NICE for a health sector perspective 
is higher than empirical estimates within the health sector.(11)  The cost per QALY for a public health 
perspective could be lower than the health sector; the median cost per QALY for public health 
interventions considered by NICE is £7,843.(13) The level of health inequality aversion is also 
uncertain and can be difficult to measure without bias. UK estimates range from 5.4 to 28.9.(23, 24)  
However, our results were not particularly sensitive to variation in this parameter.
We based the socioeconomic distribution of the health opportunity costs on the characteristics of 
beneficiaries from NHS spend. Targeting of public health interventions to disadvantaged groups could 
imply that the health opportunity costs fall even more on disadvantaged groups in comparison to NHS 
expenditure, but we did not identify evidence for this.  If true, it implies that we underestimated the 
reduction in health inequality from cost savings and the increase in health inequality from additional 
costs.  Our method assumes that funds used to provide public health interventions would otherwise 
have been spent on health generating activities.  This ignores how opportunity cost may differ where 
public health interventions impose costs across different sectors with interests outside of health 
improvement.  However, previous research has shown that healthcare costs are the predominant 
category of cost impact within NICE public health guidance.(25)  
Previously Owen et al. examined the cost-effectiveness of public health interventions underpinning 
NICE public health guidance.(13, 26)  Our study is the first to examine the health inequality impacts 
of those same interventions, and follows the same principles outlined for full distributional cost 
effectiveness analysis.(7)  McAuley et al. modelled the impact of a range of policies on population 
health and inequality by IMD in Scotland.(27)  They did not assume 100% reach for all interventions, 
but as the assumed equal uptake across population groups their health inequality impacts would be 

































































expected to be smaller but in the same direction as our estimates.  However, their analysis did not 
include health opportunity costs.  For public health interventions they found impacts on health 
inequality of similar magnitude and direction to those presented here.  
Future applications of this method should seek to incorporate evidence on differential uptake, and to 
carefully consider the implications where there exists evidence of differential effectiveness between 
socioeconomic groups.  Ongoing research to estimate both the mean and the socioeconomic 
distribution of the health opportunity cost specific to public health investments and to explore how 
this varies across the public sector will boost the application of this method. 
This method is fast, requires little data above that routinely produced to support public health 
guidelines, and provides information about the potential magnitude of health inequality impacts to 
support recommendations.  The Health and Social Care Act of 2012 introduced legal duties for 
decisions in the NHS to be made with due regard to reduce health inequalities.  Our analysis 
demonstrates that a simple distributional cost effectiveness analysis framework is feasible and could 
provide additional information on which to base recommendations for health interventions.  The 
proposed use is within a deliberative decision making process that takes account of factors outside of 
the economic calculations, such as the quality of the underlying evidence.  In the current cost 
constrained funding environment for public health, consideration of the socioeconomic distribution of 
the health opportunity cost is vital to ensure that new investments perform better than existing 
activities for the most disadvantaged.  Showing the location of public health interventions on the 
health equity impact plane could draw attention to, and prompt further examination for, interventions 
found to have negative impacts.(28)  Presenting the results using equally distributed equivalent health 
can demonstrate the added social value of reducing health inequality over and above improvements in 
total population health, and could be a useful tool for advocating increased investment in public 
health.  
Acknowledgments: The authors would like to acknowledge Karl Claxton and Richard Cookson for 
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extraction.
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Impact Recommended Not recommended % Recommended
Increases total health and reduces inequality 57 (67%) 13 (27%) 84
Increases total health and increases inequality 14 (16%) 2 (4%) 86
Reduces total health and reduces inequality 3 (4%) 2 (4%) 50
Reduces total health and increases inequality 11 (13%) 32 (65%) 26
Overall 85 49 63





































































PH50 Domestic violence and abuse 10,862,451 0.2317 12,890,044 12,524,194
PH15 Coronary heart disease 5,835,560 0.1496 7,876,529 7,568,577
PH41 Walking and cycling 5,329,142 -0.0015 5,421,791 5,309,340
PH35
Type 2 diabetes prevention: population and 
community level
786,051 0.0724 1,866,502 1,734,321
PH45 Smoking: harm reduction 594,011 0.0110 750,737 724,712
PH14 Child smoking prevention 171,359 0.0031 215,036 207,693
PH17 Physical activity in children 169,267 -0.0009 163,623 160,766
PH19 Reducing absenteeism 121,518 0.0009 132,345 128,993
PH24 Preventing and treating alcohol-use disorders 118,338 -0.0009 123,023 119,042
NG22
Older people with social care needs and 
multiple long-term conditions
18,033 0.0048 93,719 84,952
NG32
Older people: independence and mental 
wellbeing
83,144 0.0005 89,281 87,137
NG21 Home care for older people 111,340 -0.0023 88,568 88,356
NG27
Inpatient hospital and community or care home 
transition
82,582 0.0002 87,948 85,872
PH4 Substance misuse interventions for under 25s 64,550 0.0019 80,637 78,126
PH43 Hepatitis B and C testing 56,046 0.0010 69,947 67,673
PH28 Looked-after children and young people 23,757 0.0003 27,551 26,765
PH38 Type 2 diabetes prevention: people at high risk 10,251 0.0001 12,446 12,051
PH23
School-based interventions for smoking 
cessation
4,529 0.0001 7,431 7,043
NG34 Sunlight exposure 5,449 -0.0000 5,583 5,445
PH26 Smoking cessation for pregnant women 3,280 0.0001 4,101 3,965
PH20
Emotional and social wellbeing in secondary 
schools
2,588 -0.0000 2,219 2,197
NG55
Harmful sexual behaviour (HSB) among 
children and young people
1,717 0.0000 2,010 1,951
NG33 Tuberculosis 866 0.0001 1,654 1,553
PH3 STI Infection and Teenage Conception 1,260 -0.0000 1,445 1,397
PH30
Unintentional injuries in the home for under 
15s
-258 0.0000 290 232
PH21 Immunisation programmes 23 0.0000 25 25
PH29
Unintentional injuries: prevention strategies for 
under 15s
-583 -0.0000 -805 -778
PH31
Unintentional injuries on the road for under 
15s
-1,067 -0.0000 -1,323 -1,284
PH54 Physical activity: exercise referral schemes -2,325 -0.0001 -3,584 -3,442
NG6 Excess winter deaths and illness -1,116,696 -0.0167 -1,285,862 -1,250,886
 
































































PH43 Hepatitis B and C testing
This guideline contributed five interventions to the analysis.  This worked example focussed on one: the use 
of dried blood spot testing in specialist addiction services.
(i) The economic evaluation reported total incremental costs of £917,478 and incremental quality-adjusted 
life years (QALYs) of 63.  
The target population was injecting drug users (IDU), aged 15-59, in contact with specialist services.  The 
economic evaluation submitted to NICE indicated that 0.65% of the population aged 15-59 are current IDU, 
25% of whom are undiagnosed and in contact with specialist addiction services.  We multiply these by the 
2011 UK census figure of 37,899,000 individuals aged 15-59 to obtain a target population size of 61,586.
Note that if per person incremental costs (£14.90) and QALYs (0.001) had been reported, these would have 
been multiplied by population size.
(ii) This guideline targets the diseases Hepatitis B and C, which map to ICD codes B17, B18 B19.
The subgroup sizes are determined using the proportion of NHS activity by gender and ICD code.  We report 
the calculations for females, who constitute 48% of all NHS activity in this ICD code.  The same approach 
applied to males provides the subgroup sizes within the remaining 52%.
The distribution of NHS hospital activity by IMD quintile for females in these ICD codes is, in order from 
most deprived to least deprived, 0.14, 0.11, 0.11, 0.07 and 0.06. 
(iii) The same health opportunity cost of one QALY per £20,000 applies for all interventions. The total 
population cost in terms of health opportunity costs is £917,478/£20,000 = 46 QALYs.
(iv) The distribution of this opportunity cost is the same for all interventions.  In females, the order from most 
deprived to least deprived IMD quintile is 0.14, 0.12, 0.12, 0.09, and 0.08.
(v) Calculation of the distribution of net benefits by index of multiple deprivation quintile (IMD) for females 
from dried blood spot testing for Hepatitis B and C
 IMD1 IMD2 IMD3 IMD4 IMD5
(a) Proportion of health benefits 0.14 0.11 0.11 0.07 0.06
(b) Total health benefits (a*63) 8.7 6.8 6.8 4.4 3.7
(c) Proportion of health opportunity costs 0.14 0.12 0.12 0.09 0.08
(d) Total health opportunity costs (c*46) 6.4 5.5 5.5 4.1 3.7
(e) Net benefits (b-d) 2.3 1.3 1.3 0.3 0.0
Note: Health is measured in terms of quality-adjusted life years; IMD1 is the most deprived quintile

































































Influence diagram demonstrating how data are combined to estimate the net distributional effect of 
interventions. 
Footnote 1. Intervention costs are converted into health opportunity costs using a cost-effectiveness 
threshold of £20,000 per QALY. 
160x139mm (150 x 150 DPI) 

































































Health equity impact plane for PHAC recommended interventions 
Footnote: Axes are subject to an inverse hyperbolic sine transformation and reduction in SII is multiplied by 
104 to allow all interventions to be displayed on a single plane 
282x176mm (72 x 72 DPI) 

































































Health equity impact plane for interventions not recommended by the PHAC 
Footnote: Axes are subject to an inverse hyperbolic sine transformation and reduction in SII is multiplied by 
104 to allow all interventions to be displayed on a single plane 
282x176mm (72 x 72 DPI) 

































































Health equity impact plane for PHAC recommended interventions by guideline 
Footnote: Axes are subject to an inverse hyperbolic sine transformation and reduction in SII is multiplied by 
104 to allow all guidelines to be displayed on a single plane 
282x176mm (72 x 72 DPI) 

































































Table A1: Guidelines in the analysis alongside total number of included interventions and number 
recommended
Interventions in guideline
Code Topic Included Recommended
NG21 Home care for older people 1 1
NG22 Older people with social care needs and multiple long-term conditions 1 1
NG27 Inpatient hospital and community or care home transition 4 3
NG30 Oral health promotion 2 0
NG32 Older people :independence and mental wellbeing 2 2
NG33 Tuberculosis 6 4
NG34 Sunlight exposure 5 2
NG55 Harmful sexual behaviour (HSB) among children and young people 2 2
NG6 Excess winter deaths and illness 14 5
PH3 STI Infection and Teenage Conception 2 2
PH4 Substance misuse interventions for under 25s 4 1
PH14 Child smoking prevention 2 2
PH15 CHD - Smokers 22 18
PH17 Physical activity in children 4 1
PH19 Reducing absenteeism 3 3
PH20 Emotional and social wellbeing in secondary schools 1 1
PH21 Immunisation programmes 2 2
PH23 School-based interventions for smoking cessation 1 1
PH24 Preventing and treating alcohol-use disorders 1 1
PH26 Smoking cessation for pregnant women 5 5
PH28 Looked-after children and young people 2 2
PH29 Unintentional injuries: prevention strategies for under 15s 1 1
PH30 Unintentional injuries in the home: interventions for under 15s 1 1
PH31 Unintentional injuries on the road for under 15s 4 2
PH32 Information to prevent skin cancer 8 0
PH35 Diabetes prevention 5 3
PH38 Diabetes prevention 3 1
PH40 Social and emotional wellbeing: early years 4 0
PH41 Walking and cycling 6 4
PH43 Hepatitis B and C testing 5 5
PH45 Smoking:harm reduction 4 4
PH50 Domestic violence and abuse: multi-agency working 2 2
PH54 Physical activity: exercise referral schemes 4 3

































































Figure A1: Flow diagram showing reasons for exclusion of guidelines
Note: NICE = National Institute of Health and Care Excellence; QALY = quality adjusted life year
Table A2: Guidelines excluded, or containing interventions excluded, from the study 
Reason for exclusion Guideline codes
Guidance replaced and obsolete PH2, PH9
No economic modelling / benefits not 
expressed in QALYs
PH7, PH10, PH11, PH13, PH18, PH25, PH33, PH34, PH36, PH39, 
PH42, PH44, PH46, PH47, PH48, PH49, PH51, PH52, PH53, 
PH55, PH56, NG7, NG44, NG48
Incremental costs and QALYs not 
reported separately
PH1, PH6, PH12
Specific interventions not modelled PH8, PH21, NG13
Intervention costs funded by employers PH5, PH22
Includes interventions where data on 
population or distribution was not 
available (number excluded)
PH15 (2), PH38 (1)
Includes interventions with no reported 
QALYs (number excluded)
NG30 (1), NG27 (1), NG32 (2)
 









































































Outpatient geriatric multidisciplinary 
assessment and case management intervention
Yes 1,091 187 -904
PH15 Dentist-based interventions Yes 15,133 6,383 -8,750
PH15 Free mobile phones No 76,139 10,379 -65,760
PH15 Free NRT No 8,426 6,292 -2,133
PH15 ID smokers through other means Yes 21,985 -1 -21,987
PH15 Pharmacist-based interventions Yes 9,081 3,992 -5,089
PH15 Pharmacist-based interventions (deprived area) Yes 27,111 1,363 -25,748
PH15 Proactive telephone counselling Yes 22,721 1,582 -21,140
PH15 Recruitment to 'Quit and Win' Yes 27,476 738 -26,738
PH15 Social marketing (African Americans) Yes 114 0 -114
PH15 Pharmacist-based interventions (CHD) Yes 659 -28 -687
PH24 Screening and brief intervention Yes 103 -94 -197
PH28 Transition support services (females) Yes 11 -5 -16
PH28 Transition support services (males) Yes 51 15 -36
PH3 Accelerated Partner Therapy Yes 1 0 0
PH3 Counselling Yes 3 -9 -12
PH32 Multicomponent in community No -1 -1 0
PH32 Multicomponent in healthcare setting No -3 -3 0
PH32 Verbal advice No 0 -8 -8
PH4 Life skills training Yes 180 22 -158
PH41 Led walking Yes 9 -22 -31
PH41 Pedometer Yes 343 -13 -356
PH41 TravelSmart Yes 2,818 157 -2,661
PH45
Quit and substitute with long-term nicotine use 
with generic professional behavioural support
Yes 4,235 29 -4,207
PH45
Temporary abstinence or reduce smoking with 
specialist services behavioural support
Yes 630 -3,586 -4,216
PH54 Exercise referral scheme No -69 -61 9
PH54 Exercise referral scheme (depression) Yes -11 -12 -2
PH54 Exercise referral scheme (hypertension) Yes -32 -33 -1
PH54 Exercise referral scheme (obese) Yes -14 -15 -2

































































Figure A2: Social welfare rank order of each guideline: left hand side when only total health benefit 
is considered (no inequality aversion); right hand side when there is large concern for health 
inequality
Note: No inequality aversion equates to the parameter ε in the Atkinson Welfare Index set to 0. For high inequality aversion, 
ε=20.

































































Figure A3: Effect of the cost-effectiveness threshold on the reduction SII from implementing all 
guidelines

































































Table A4: Intervention characteristics of extracted NICE public health interventions
Topic Intervention Code QALY Cost Population Recommended
Home care for older people
Social care services provided as part of care package for 
people living in own home and care planning approach
NG21.1 0.02 £107 7,600,000 Yes
Older people with social care needs and multiple 
long-term conditions
Outpatient geriatric multidisciplinary assessment and case 
management intervention
NG22.2 0.17 £1,240 683,070 Yes
Inpatient hospital and community or care home 
transition
Multidisciplinary palliative care teams NG27.1 0 -£1,789 200,000 Yes
Inpatient hospital and community or care home 
transition
Early supported discharge following stroke NG27.2 0.47 £5,000 152,000 Yes
Inpatient hospital and community or care home 
transition
Early supported discharge older people NG27.3 0.02 -£1,727 291,000 Yes
Inpatient hospital and community or care home 
transition
Specialised geriatric intervention for older people presenting 
with undifferentiated confusion
NG27.4 0 £933 76,000 No
Oral health promotion One-to-one health counselling NG30.1 0.0002 £225 464,422 No
Oral health promotion One-to-one health counselling NG30.2 0.0003 £166 89,856 No
Older people:independence and mental wellbeing Internet and computer training intervention NG32.1 0.02 £340 3,040,000 Yes
Older people:independence and mental wellbeing Friendship programmes NG32.2 0.04 -£314 3,040,000 Yes
Tuberculosis Mobile X-ray unit screening (homeless) NG33.1 0.083 -£920 4,134 Yes
Tuberculosis Enhanced case-management (homeless) NG33.2 0.093 -£3,470 33 Yes
Tuberculosis
Mobile X-ray screening and enhanced case-management 
(homeless)
NG33.3 0.138 -£3,580 4,134 Yes
Tuberculosis Mobile X-ray unit screening (prisoners) NG33.4 0.013 £280 85,975 No
Tuberculosis Enhanced case-management (prisoners) NG33.5 0.013 -£1,340 179 Yes
Tuberculosis
Mobile X-ray screening and enhanced case-management 
(prisoners)
NG33.6 0.018 -£330 85,975 No
Sunlight exposure Information programme for schoolchildren NG34.1 0 £15 641,065 No
Sunlight exposure Photoageing NG34.2 0 £12 1,479,039 No
Sunlight exposure Text messaging NG34.3 0.0001 £4 16,654,773 No
Sunlight exposure Tailored messages NG34.4 0.0003 £4 641,065 Yes
Sunlight exposure Mass media campaign NG34.5 0.0001 £0 53,844,267 Yes



















































Harmful sexual behaviour (HSB) among children 
and young people
 Multi-systemic therapy NG55.1 0.061 -£9,551 4,209 Yes
Harmful sexual behaviour (HSB) among children 
and young people
 Cognitive behavioural therapy NG55.2 0.035 -£4,847 4,209 Yes
Excess winter deaths and illness Home energy efficiency intervention NG6.1 0.048 £1,358 895,280 Yes
Excess winter deaths and illness Home energy efficiency intervention NG6.10 0.002 £1,493 6,099,082 Yes
Excess winter deaths and illness £200 fuel subsidy intervention NG6.11 0.001 £1,127 6,099,082 No
Excess winter deaths and illness Home energy plus fuel subsidy NG6.12 0.002 £2,358 6,099,082 No
Excess winter deaths and illness Home energy efficiency intervention NG6.13 0.001 £1,430 4,545,404 Yes
Excess winter deaths and illness £200 fuel subsidy intervention NG6.14 0.001 £1,128 4,545,404 No
Excess winter deaths and illness Home energy plus fuel subsidy NG6.15 0.002 £2,311 4,545,404 No
Excess winter deaths and illness £200 fuel subsidy intervention NG6.2 0.032 £1,122 895,280 No
Excess winter deaths and illness Home energy plus fuel subsidy NG6.3 0.073 £2,210 895,280 No
Excess winter deaths and illness Home energy efficiency intervention NG6.4 0.006 £1,456 1,699,129 Yes
Excess winter deaths and illness £200 fuel subsidy intervention NG6.5 0.004 £1,130 1,699,129 No
Excess winter deaths and illness Home energy plus fuel subsidy NG6.6 0.008 £2,314 1,699,129 No
Excess winter deaths and illness Home energy efficiency intervention NG6.7 0.001 £1,500 2,965,131 Yes
Excess winter deaths and illness £200 fuel subsidy intervention NG6.8 0.0007 £1,130 2,965,131 No
Excess winter deaths and illness Home energy plus fuel subsidy NG6.9 0.002 £2,350 2,965,131 No
Child smoking prevention Mass media campaign PH14.1 0.1 £5 3,147,089 Yes
Child smoking prevention Point of sale intervention PH14.2 0.01 £17 3,147,089 Yes
CHD - Smokers  Recruiting smokers from community PH15.10 1.7 £17 10,210,770 Yes
CHD - Smokers  Recruitment to 'Quit and Win' PH15.11 0.69 £53 10,210,770 Yes
CHD - Smokers  ID smokers through other means PH15.13 0.55 £6 10,210,770 Yes
CHD - Smokers  Dentist-based interventions PH15.15 0.38 £75 10,210,770 Yes
CHD - Smokers  Drop-in community-based sessions PH15.16 0.03 £22 10,210,770 Yes
CHD - Smokers  Pharmacist-based interventions (smokers) PH15.17 0.23 £121 10,210,770 Yes
CHD - Smokers  Free NRT PH15.20 0.21 £6 10,210,770 No
CHD - Smokers  Social marketing PH15.21 0.02 £1 10,210,770 Yes



















































CHD - Smokers  Workplace smoking cessation + incentives PH15.22 0.55 £55 10,210,770 Yes
CHD - Smokers (disadvantaged)  Social marketing (african americans) PH15.24 0.07 £86 428,925 Yes
CHD - Smokers (disadvantaged)  Recruitment at pediatric unit PH15.25 0.14 £155 94,363 Yes
CHD - Smokers (disadvantaged)  NHS SSS (deprived men) PH15.26 0.43 £196 887,244 Yes
CHD - Smokers (disadvantaged)  NHS SSS (deprived women) PH15.27 0.38 £196 717,652 Yes
CHD - Smokers (disadvantaged)  Pharmacist-based interventions (deprived area) PH15.28 0.77 £151 1,604,897 Yes
CHD - Smokers (disadvantaged)  NRT prescription (deprived area) PH15.30 0.39 £230 1,604,897 Yes
CHD - Smokers (disadvantaged)  Brief intervention for low income  pregnant women PH15.31 0.37 £211 139,570 No
CHD - Smokers  Free mobile phones PH15.32 1.94 £68 10,210,770 No
CHD - Smokers (disadvantaged)  Proactive telephone support for pregnant women PH15.33 0.06 £140 697,852 No
CHD - Statin use  Pharmacist-based interventions (CHD) PH15.34 0.08 £230 2,300,000 Yes
CHD - Smokers  Interventions at cervical screening PH15.37 0.21 £18 10,210,770 Yes
CHD - Smokers  Nurse run clinics PH15.6 0.58 £53 10,210,770 Yes
CHD - Smokers  Proactive telephone counselling PH15.8 0.57 £52 10,210,770 Yes
Physical activity in children Walking bus' PH17.1 0.03 £124 7,112,050 Yes
Physical activity in children Dance classes PH17.2 0.002 £58 7,112,050 No
Physical activity in children Free swimming PH17.3 0.0001 £5 7,112,050 No
Physical activity in children Community sports scheme PH17.4 0.0002 £16 7,112,050 No
Reducing absenteeism Workplace intervention PH19.1 0.12 -£304 539,000 Yes
Reducing absenteeism Physical activity and education PH19.2 0.06 £77 539,000 Yes
Reducing absenteeism Workplace intervention +  physical activity and education PH19.3 0.44 -£900 539,000 Yes
Emotional and social wellbeing in secondary 
schools
Classroom intervention / peer mediation to prevent bullying PH20.1 0.002 £16 3,234,875 Yes
Immunisation programmes Increasing first dose coverage to 100% PH21.1 0.002 -£2 2,415 Yes
Immunisation programmes Increasing 2nd to 4th doses to 100% PH21.2 0.007 -£7 2,415 Yes
School-based interventions for smoking cessation Generic school-based  programme PH23.1 0.003 £46 7,547,800 Yes
Preventing and treating alcohol-use disorders Screening and brief intervention PH24.2 0.002 -£1 52,594,874 Yes
Smoking cessation for pregnant women Cognitive behaviour strategies PH26.1 0.032 £126 76,066 Yes



















































Smoking cessation for pregnant women Stages of change PH26.2 0.007 £20 76,066 Yes
Smoking cessation for pregnant women Feedback PH26.3 0.049 £97 76,066 Yes
Smoking cessation for pregnant women Rewards PH26.4 0.111 -£52 76,066 Yes
Smoking cessation for pregnant women Pharmacotherapies PH26.5 0.032 £71 76,066 Yes
Looked-after children and young people Transition support services (males) PH28.1 0.61 -£76,546 4,151 Yes
Looked-after children and young people Transition support services (females) PH28.3 0.38 -£23,825 3,397 Yes
Unintentional injuries: prevention strategies for 
under 15s
20mph zones in high casualty areas PH29.1 0.0003 £11 2,150,000 Yes
STI Infection and Teenage Conception Accelerated Partner Therapy PH3.1 0.003 £28 434,456 Yes
STI Infection and Teenage Conception Counselling PH3.3 0.005 £16 434,456 Yes
Unintentional injuries in the home: interventions for 
under 15s
Free smoke alarms PH30.1 0.0001 £3 4,956,173 Yes
Unintentional injuries on the road for under 15s Mixed priority routes PH31.1 0.002 £502 10,750,000 No
Unintentional injuries on the road for under 15s Mandatory 20mph zone (low casualty area) PH31.2 0.00003 £13 860,000 No
Unintentional injuries on the road for under 15s Mandatory 20mph zone (high casualty area) PH31.3 0.00014 £13 2,150,000 Yes
Unintentional injuries on the road for under 15s Advisory 20mph zone PH31.4 0.00002 £1 5,375,000 Yes
Information to prevent skin cancer Verbal advice PH32.1 0.0001 £1 7,112,050 No
Information to prevent skin cancer Multicomponent in work-setting PH32.11 0 £52 31,977,862 No
Information to prevent skin cancer Verbal advice PH32.3 0.0001 £2 1,697,150 No
Information to prevent skin cancer Provision of shade PH32.4 0 £2 3,063,720 No
Information to prevent skin cancer Multicomponent in beaches and pools PH32.5 0 £20 2,669,852 No
Information to prevent skin cancer Multicomponent in community PH32.7 0 £1 6,688,036 No
Information to prevent skin cancer Multicomponent in educational setting PH32.8 0 £4 3,460,510 No
Information to prevent skin cancer Multicomponent in healthcare setting PH32.9 0 £12 1,790,978 No
Diabetes prevention  Education to increase fruit and veg intake PH35.1 0 £44 7,864,447 No
Diabetes prevention  Dietary education / cooking skills PH35.2 0.013 £11 7,864,447 Yes
Diabetes prevention  Open new food outlet PH35.3 0 £0 7,864,447 No
Diabetes prevention  Multi-component small scale PH35.4 0.138 £78 7,864,447 Yes
Diabetes prevention  Multi-component large scale PH35.5 0.127 £19 7,864,447 Yes



















































Diabetes prevention LPDS > 5.25, HbA1c > 6% (with intensive intvn) PH38.1 0.012 £131 2,070,854 Yes
Diabetes prevention LPDS > 5, HbA1c > 5.85% (with intensive intvn) PH38.2 0.021 £234 2,070,854 No
Diabetes prevention LPDS > 4.75, HbA1c > 5.7% (with intensive intvn) PH38.3 0.039 £472 2,070,854 No
Substance misuse interventions for under 25s Life skills training PH4.1 0.019 £25 3,576,155 Yes
Substance misuse interventions for under 25s Say Yes First PH4.3 0.021 £1,900 3,351,895 No
Substance misuse interventions for under 25s Teacher training PH4.4 0.002 £236 7,112,050 No
Substance misuse interventions for under 25s The Abecedarian Project PH4.5 0.04 £7,800 4,299,430 No
Social and emotional wellbeing: early years Weekly home visits PH40.1 0.032 £2,711 21,136 No
Social and emotional wellbeing: early years SureStart Cognition for Age 5 PH40.2 0.354 -£10,656 21,660 No
Social and emotional wellbeing: early years Sure Start Age 3 (3 years) PH40.3 0.07 £1,059 22,446 No
Social and emotional wellbeing: early years Sure Start Age 3 (5 years) PH40.4 0.372 -£6,959 22,446 No
Walking and cycling Multi component: cycling demonstration towns PH41.1 0.0062 £30 52,276,421 No
Walking and cycling Multi component: sustainable travel towns PH41.2 0.044 £47 52,276,421 No
Walking and cycling TravelSmart PH41.3 0.093 £25 52,276,421 Yes
Walking and cycling Pedometer PH41.6 0.359 £268 4,029,973 Yes
Walking and cycling Led walking PH41.7 0.025 £47 4,029,973 Yes
Walking and cycling Get walking keep walking PH41.9 0.020 £55 4,029,973 Yes
Hepatitis B and C testing Dried blood spot testing in specialist addiction services  PH43.1 0.001 £15 61,586 Yes
Hepatitis B and C testing Dried blood spot testing to prison services PH43.2 0.0002 £14 75,798 Yes
Hepatitis B and C testing
 GP education and paid targeted testing of former IDU 30-54 
years old
PH43.3 0.0027 £37 91,150 Yes
Hepatitis B and C testing Case finding PH43.4 0.0022 £46 348,880 Yes
Hepatitis B and C testing Case finding PH43.5 0.163 £45 348,880 Yes
Smoking:harm reduction CDTQ with generic professional BS PH45.1 0.1 -£146 10,210,770 Yes
Smoking:harm reduction
Quit and substitute with long-term nicotine use with generic 
professional BS
PH45.2 0.114 £274 10,210,770 Yes
Smoking:harm reduction
Temporary abstinence or reduce smoking with specialist 
services BS
PH45.4 0.021 £169 10,210,770 Yes
Smoking:harm reduction Reduce amount smoking with specialist services BS PH45.6 0.021 £169 10,210,770 Yes



















































Domestic violence and abuse: multi-agency 
working
Independent domestic violence advisors PH50.1 0.08 -£47,000 745,000 Yes
Domestic violence and abuse: multi-agency 
working
Cognitive trauma therapy _ battered women PH50.2 1.02 -£150,000 745,000 Yes
Physical activity: exercise referral schemes Exercise referral scheme (healthy) PH54.2 0.007 £217 1,865,449 No
Physical activity: exercise referral schemes Exercise referral scheme (obese) PH54.4 0.008 £214 621,816 Yes
Physical activity: exercise referral schemes Exercise referral scheme (hyp) PH54.6 0.007 £216 1,154,802 Yes
Physical activity: exercise referral schemes Exercise referral scheme (dep) PH54.8 0.009 £214 532,985 Yes



















































Table A5: Inequality impact of interventions











Home care for older people NG21.1 111,340 -0.0023 0.0000 +- 88,568 88,356 36 43 -7
Older people with social care needs and multiple long-term 
conditions
NG22.2 73,772 0.0048 0.0001 ++ 93,719 84,952 54 37 17
Inpatient hospital and community or care home transition NG27.1 17,890 0.0003 0.0000 ++ 20,627 20,062 55 57 -2
Inpatient hospital and community or care home transition NG27.2 33,744 -0.0004 0.0000 +- 33,163 32,502 45 54 -9
Inpatient hospital and community or care home transition NG27.3 30,948 0.0003 0.0000 ++ 34,158 33,308 47 52 -5
Inpatient hospital and community or care home transition NG27.4 -3,545 -0.0001 0.0000 -- -4,088 -3,976 108 108 0
Oral health promotion NG30.1 -5,132 -0.0001 0.0000 -- -5,906 -5,745 111 110 1
Oral health promotion NG30.2 -719 0.0000 0.0000 -- -826 -803 98 97 1
Older people:independence and mental wellbeing NG32.1 12,160 -0.0004 0.0000 +- 9,084 9,059 58 62 -4
Older people:independence and mental wellbeing NG32.2 154,128 0.0014 0.0000 ++ 169,477 165,214 32 35 -3
Tuberculosis NG33.1 533 0.0001 0.0000 ++ 1,643 1,537 74 72 2
Tuberculosis NG33.2 9 0.0000 0.0000 ++ 19 18 84 85 -1
Tuberculosis NG33.3 1,311 0.0001 0.0000 ++ 3,227 3,036 71 68 3
Tuberculosis NG33.4 -112 0.0002 0.0000 -+ 3,511 3,201 73 65 8
Tuberculosis NG33.5 14 0.0000 0.0000 ++ 24 23 82 83 -1
Tuberculosis NG33.6 2,966 0.0003 0.0000 ++ 8,578 8,041 64 60 4
Sunlight exposure NG34.1 -481 0.0000 0.0000 -- -554 -539 94 94 0
Sunlight exposure NG34.2 -887 0.0000 0.0000 -- -1,023 -995 99 100 -1
Sunlight exposure NG34.3 -1,665 0.0000 0.0000 -- -2,192 -2,117 104 105 -1
Sunlight exposure NG34.4 64 0.0000 0.0000 +- 37 39 80 87 -7
Sunlight exposure NG34.5 5,384 0.0000 0.0000 +- 5,546 5,406 61 64 -3
Harmful sexual behaviour (HSB) among children and young 
people
NG55.1 2,267 0.0000 0.0000 ++ 2,651 2,574 67 70 -3
Harmful sexual behaviour (HSB) among children and young 
people
NG55.2 1,167 0.0000 0.0000 ++ 1,368 1,327 72 75 -3
Excess winter deaths and illness NG6.1 -18,174 -0.0003 0.0000 -- -21,603 -20,954 115 115 0



















































Excess winter deaths and illness NG6.10 -445,538 -0.0069 -0.0001 -- -516,270 -501,994 131 131 0
Excess winter deaths and illness NG6.11 -338,194 -0.0052 -0.0001 -- -391,378 -380,585 129 129 0
Excess winter deaths and illness NG6.12 -706,274 -0.0109 -0.0002 -- -817,724 -795,142 133 133 0
Excess winter deaths and illness NG6.13 -319,996 -0.0044 -0.0001 -- -363,150 -353,714 128 128 0
Excess winter deaths and illness NG6.14 -253,179 -0.0035 -0.0001 -- -288,220 -280,652 127 126 1
Excess winter deaths and illness NG6.15 -517,949 -0.0072 -0.0001 -- -588,760 -573,374 132 132 0
Excess winter deaths and illness NG6.2 -21,755 -0.0003 0.0000 -- -25,516 -24,780 116 116 0
Excess winter deaths and illness NG6.3 -33,483 -0.0005 0.0000 -- -39,601 -38,429 117 117 0
Excess winter deaths and illness NG6.4 -114,351 -0.0018 0.0000 -- -132,476 -128,829 121 121 0
Excess winter deaths and illness NG6.5 -90,054 -0.0014 0.0000 -- -104,232 -101,366 120 120 0
Excess winter deaths and illness NG6.6 -183,336 -0.0029 -0.0001 -- -212,279 -206,439 123 123 0
Excess winter deaths and illness NG6.7 -218,530 -0.0033 -0.0001 -- -252,269 -245,339 124 124 0
Excess winter deaths and illness NG6.8 -165,454 -0.0025 0.0000 -- -190,931 -185,692 122 122 0
Excess winter deaths and illness NG6.9 -343,066 -0.0051 -0.0001 -- -395,979 -385,105 130 130 0
Child smoking prevention PH14.1 313,922 0.0057 0.0001 ++ 393,684 380,263 24 25 -1
Child smoking prevention PH14.2 28,796 0.0005 0.0000 ++ 36,377 35,116 49 49 0
CHD - Smokers PH15.10
17,349,63
0
0.3151 0.0052 ++ 21,675,974 20,964,248 2 2 0
CHD - Smokers PH15.11 7,018,373 0.1275 0.0021 ++ 8,790,001 8,494,619 3 3 0
CHD - Smokers PH15.13 5,612,860 0.1019 0.0017 ++ 7,029,955 6,793,131 7 7 0
CHD - Smokers PH15.15 3,841,802 0.0699 0.0012 ++ 4,817,175 4,653,996 10 9 1
CHD - Smokers PH15.16 295,091 0.0054 0.0001 ++ 371,128 358,394 26 26 0
CHD - Smokers PH15.17 2,286,702 0.0417 0.0007 ++ 2,872,125 2,774,205 11 14 -3
CHD - Smokers PH15.20 2,141,198 0.0389 0.0007 ++ 2,683,960 2,592,844 13 15 -2
CHD - Smokers PH15.21 203,705 0.0037 0.0001 ++ 255,468 246,757 29 29 0
CHD - Smokers PH15.22 5,587,844 0.1016 0.0017 ++ 7,001,147 6,765,095 8 8 0
CHD - Smokers (disadvantaged) PH15.24 28,180 0.0005 0.0000 ++ 35,522 34,296 50 51 -1
CHD - Smokers (disadvantaged) PH15.25 12,480 0.0013 0.0000 ++ 34,092 31,639 57 46 11



















































CHD - Smokers (disadvantaged) PH15.26 372,820 0.0386 0.0006 ++ 997,033 926,153 23 22 1
CHD - Smokers (disadvantaged) PH15.27 265,675 0.0276 0.0004 ++ 712,128 661,410 25 24 1
CHD - Smokers (disadvantaged) PH15.28 1,223,654 0.1254 0.0019 ++ 3,234,165 3,006,849 17 11 6
CHD - Smokers (disadvantaged) PH15.30 607,454 0.0633 0.0009 ++ 1,628,894 1,513,140 22 16 6
CHD - Smokers (disadvantaged) PH15.31 50,168 0.0052 0.0001 ++ 134,838 125,209 42 32 10
CHD - Smokers PH15.32
19,774,17
7
0.3592 0.0060 ++ 24,694,850 23,888,137 1 1 0
CHD - Smokers (disadvantaged) PH15.33 36,986 0.0007 0.0000 ++ 46,870 45,234 44 45 -1
CHD - Statin use PH15.34 157,550 0.0029 0.0000 ++ 200,216 193,186 31 30 1
CHD - Smokers PH15.37 2,135,072 0.0878 0.0015 ++ 2,323,861 2,287,101 14 18 -4
CHD - Smokers PH15.6 5,895,188 0.1071 0.0018 ++ 7,385,488 7,136,663 5 4 1
CHD - Smokers PH15.8 5,793,591 0.1053 0.0018 ++ 7,258,360 7,013,764 6 6 0
Physical activity in children PH17.1 169,267 -0.0009 0.0000 +- 163,623 160,766 30 36 -6
Physical activity in children PH17.2 -6,401 -0.0003 0.0000 -- -9,482 -9,115 112 112 0
Physical activity in children PH17.3 -1,067 0.0000 0.0000 -- -1,335 -1,293 102 103 -1
Physical activity in children PH17.4 -4,267 -0.0001 0.0000 -- -5,130 -4,979 109 109 0
Reducing absenteeism PH19.1 72,873 0.0005 0.0000 ++ 79,513 77,494 39 41 -2
Reducing absenteeism PH19.2 30,265 0.0002 0.0000 ++ 32,641 31,826 48 53 -5
Reducing absenteeism PH19.3 261,415 0.0019 0.0000 ++ 284,877 277,657 27 28 -1
Emotional and social wellbeing in secondary schools PH20.1 2,588 0.0000 0.0000 +- 2,219 2,197 66 74 -8
Immunisation programmes PH21.1 5 0.0000 0.0000 ++ 6 5 85 88 -3
Immunisation programmes PH21.2 18 0.0000 0.0000 ++ 20 19 81 86 -5
School-based interventions for smoking cessation PH23.1 4,529 0.0001 0.0000 ++ 7,431 7,043 63 61 2
Preventing and treating alcohol-use disorders PH24.2 118,338 -0.0009 0.0000 +- 123,023 119,042 35 38 -3
Smoking cessation for pregnant women PH26.1 1,917 0.0000 0.0000 ++ 2,430 2,347 69 71 -2
Smoking cessation for pregnant women PH26.2 426 0.0000 0.0000 ++ 537 519 77 78 -1
Smoking cessation for pregnant women PH26.3 3,328 0.0001 0.0000 ++ 4,176 4,037 65 66 -1
Smoking cessation for pregnant women PH26.4 8,603 0.0002 0.0000 ++ 10,691 10,340 60 59 1



















































Smoking cessation for pregnant women PH26.5 2,126 0.0000 0.0000 ++ 2,671 2,582 68 69 -1
Looked-after children and young people PH28.1 18,419 0.0002 0.0000 ++ 21,552 20,913 53 56 -3
Looked-after children and young people PH28.3 5,338 0.0001 0.0000 ++ 6,000 5,852 62 63 -1
Unintentional injuries: prevention strategies for under 15s PH29.1 -583 0.0000 0.0000 -- -805 -778 96 98 -2
STI Infection and Teenage Conception PH3.1 695 0.0000 0.0000 +- 795 768 75 76 -1
STI Infection and Teenage Conception PH3.3 1,825 0.0000 0.0000 +- 2,094 2,027 70 73 -3
Unintential injuries in the home: interventions for under 15s PH30.1 -248 0.0000 0.0000 -+ 290 232 91 77 14
Unintentional injuries on the road for under 15s PH31.1 -252,286 -0.0042 -0.0001 -- -294,802 -286,582 126 127 -1
Unintentional injuries on the road for under 15s PH31.2 -550 0.0000 0.0000 -- -640 -622 95 95 0
Unintentional injuries on the road for under 15s PH31.3 -1,047 0.0000 0.0000 -- -1,274 -1,237 101 102 -1
Unintentional injuries on the road for under 15s PH31.4 -20 0.0000 0.0000 -- -49 -47 88 91 -3
Information to prevent skin cancer PH32.1 356 0.0000 0.0000 ++ 269 273 78 79 -1
Information to prevent skin cancer PH32.11 -83,142 -0.0012 0.0000 -- -95,862 -93,238 119 119 0
Information to prevent skin cancer PH32.3 0 0.0000 0.0000 ++ -9 -8 87 90 -3
Information to prevent skin cancer PH32.4 -306 0.0000 0.0000 -- -353 -344 92 92 0
Information to prevent skin cancer PH32.5 -2,670 0.0000 0.0000 -- -3,078 -2,994 107 107 0
Information to prevent skin cancer PH32.7 -334 0.0000 0.0000 -- -386 -375 93 93 0
Information to prevent skin cancer PH32.8 -692 0.0000 0.0000 -- -798 -776 97 96 1
Information to prevent skin cancer PH32.9 -1,075 0.0000 0.0000 -- -1,239 -1,205 103 101 2
Diabetes prevention PH35.1 -17,302 -0.0003 0.0000 -- -19,948 -19,403 114 114 0
Diabetes prevention PH35.2 97,126 0.0101 0.0001 ++ 258,393 239,872 37 27 10
Diabetes prevention PH35.3 0 0.0000 0.0000 ++ 0 0 86 89 -3
Diabetes prevention PH35.4 1,054,622 0.1079 0.0016 ++ 2,768,726 2,572,802 18 12 6
Diabetes prevention PH35.5 988,168 0.0993 0.0015 ++ 2,564,918 2,384,317 20 13 7
Diabetes prevention PH38.1 10,251 0.0001 0.0000 ++ 12,446 12,051 59 58 1
Diabetes prevention PH38.2 19,259 0.0003 0.0000 ++ 23,351 22,611 52 55 -3
Diabetes prevention PH38.3 32,305 0.0005 0.0000 ++ 39,386 38,120 46 47 -1
Substance misuse interventions for under 25s PH4.1 64,550 0.0019 0.0000 ++ 80,637 78,126 41 39 2



















































Substance misuse interventions for under 25s PH4.3 -248,375 -0.0027 -0.0001 -- -280,067 -272,712 125 125 0
Substance misuse interventions for under 25s PH4.4 -73,254 -0.0009 0.0000 -- -83,500 -81,262 118 118 0
Substance misuse interventions for under 25s PH4.5
-
1,504,801
-0.0201 -0.0004 -- -1,719,725 -1,673,342 134 134 0
Social and emotional wellbeing: early years PH40.1 -2,189 0.0000 0.0000 -+ -1,578 -1,610 106 99 7
Social and emotional wellbeing: early years PH40.2 19,208 0.0009 0.0000 ++ 32,859 31,108 51 48 3
Social and emotional wellbeing: early years PH40.3 383 0.0001 0.0000 ++ 2,637 2,390 76 67 9
Social and emotional wellbeing: early years PH40.4 16,160 0.0009 0.0000 ++ 30,298 28,542 56 50 6
Walking and cycling PH41.1 245,699 -0.0012 0.0000 +- 234,336 230,859 28 31 -3
Walking and cycling PH41.2 2,156,402 -0.0018 0.0001 +- 2,186,879 2,141,484 12 19 -7
Walking and cycling PH41.3 4,812,045 -0.0010 0.0002 +- 4,907,397 4,804,110 9 10 -1
Walking and cycling PH41.6 1,392,356 -0.0011 0.0001 +- 1,386,818 1,361,974 16 23 -7
Walking and cycling PH41.7 89,179 -0.0002 0.0000 +- 87,911 86,400 38 40 -2
Walking and cycling PH41.9 69,920 -0.0002 0.0000 +- 68,384 67,246 40 44 -4
Hepatitis B and C testing PH43.1 15 0.0000 0.0000 ++ 23 22 83 84 -1
Hepatitis B and C testing PH43.2 -38 0.0000 0.0000 -+ 7 4 89 82 7
Hepatitis B and C testing PH43.3 77 0.0000 0.0000 ++ 112 107 79 80 -1
Hepatitis B and C testing PH43.4 -35 0.0000 0.0000 -+ 59 50 90 81 9
Hepatitis B and C testing PH43.5 56,013 0.0010 0.0000 ++ 69,747 67,490 43 42 1
Smoking:harm reduction PH45.1 1,095,616 0.0197 0.0003 ++ 1,365,983 1,320,091 19 20 -1
Smoking:harm reduction PH45.2 1,024,140 0.0190 0.0003 ++ 1,297,979 1,252,741 21 21 0
Smoking:harm reduction PH45.4 128,145 0.0026 0.0000 ++ 169,384 162,940 33 33 0
Smoking:harm reduction PH45.6 128,145 0.0026 0.0000 ++ 169,384 162,940 33 33 0
Domestic violence and abuse: multi-agency working PH50.1 1,810,350 0.0309 0.0005 ++ 2,108,164 2,049,527 15 17 -2
Domestic violence and abuse: multi-agency working PH50.2 6,347,400 0.1432 0.0024 ++ 7,580,924 7,361,959 4 5 -1
Physical activity: exercise referral schemes PH54.2 -7,182 -0.0004 0.0000 -- -11,859 -11,348 113 113 0
Physical activity: exercise referral schemes PH54.4 -1,679 -0.0001 0.0000 -- -2,589 -2,490 105 106 -1
Physical activity: exercise referral schemes PH54.6 -4,388 -0.0002 0.0000 -- -6,537 -6,286 110 111 -1



















































Physical activity: exercise referral schemes PH54.8 -906 -0.0001 0.0000 -- -1,627 -1,550 100 104 -4
Key for Impact: ++ increase population health and reduce inequality; +- increase population health and increase inequality; -+ reduce population health and reduce inequality; -- reduce 
population health and increase inequality
Notes: Positive change (∆) in SII indicates a reduction in absolute health inequality. Positive change for the Atkinson and Kolm welfare scores indicate an increase in social welfare. Shaded 
rows indicate guidelines where increases in health inequality reduce social welfare to less than net population health benefit, i.e. EDE<NHB
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